TW-37

For research use only.

Catalog No.S1121

32 publications

TW-37 Chemical Structure

Molecular Weight(MW): 573.7

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 146 In stock
USD 160 In stock
USD 680 In stock
USD 1480 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's TW-37 has been cited by 32 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell MnzZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEnFNlZKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOkBvVQ>? M2XnTHNCVkeHUh?=
human Ca9-22 cell NV;6O4M3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2\xdWlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OiCwTR?= NUDSWodvW0GQR1XS
human CHL-1 cell Mn;0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHTBXmVKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvQSCwTR?= MUXTRW5ITVJ?
human A549 cell NUi3VFdMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEWy[4lKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE4xQSCwTR?= NUXLWlJGW0GQR1XS
human RKO cell NYe2e49HT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NY\3cGFIUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4yPyCwTR?= MXnTRW5ITVJ?
human GCIY cell M{XsUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHvTY5pcWKrdHnvckBw\iCqdX3hckBIS0m\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkCuPFMhdk1? NFvhZnJUSU6JRWK=
human BHT-101 cell NWS0fFlCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlP4TY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDNibl2= MmT6V2FPT0WU
human Hs-578-T cell NIW4UFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NILJbnBKdmirYnn0bY9vKG:oIHj1cYFvKEi|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjNwNUmgcm0> M4PPWnNCVkeHUh?=
human SK-UT-1 cell M4DjWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4rqWWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjZ6IH7N NUPFWnJGW0GQR1XS
human NB7 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{jDcGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkmuNlghdk1? M{\qZnNCVkeHUh?=
human YKG-1 cell NIfy[VhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJHlMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkmuO|Yhdk1? MVnTRW5ITVJ?
human HuH-7 cell NH7sb|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmHFTY5pcWKrdHnvckBw\iCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOyMlgzKG6P NID2cIhUSU6JRWK=
human SAS cell Ml\oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml\LTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mz6xPEBvVQ>? NXLGZ41yW0GQR1XS
human UACC-62 cell M2\S[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jyPWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjN3IH7N M2TWTnNCVkeHUh?=
human AGS cell MmjvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF\VZoVKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO3MlU{KG6P MnzvV2FPT0WU
human SK-MEL-30 cell M2XjRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{HrUWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzdwOUegcm0> M4noWnNCVkeHUh?=
human A427 cell NXzEV4VOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12ND62PUBvVQ>? Mn\XV2FPT0WU
human DU-145 cell M4LOR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnzpTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Nk4yOyCwTR?= MnfWV2FPT0WU
human HCT-116 cell Ml;2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXhbGNKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi54NjDuUS=> NEnVPW1USU6JRWK=
human A673 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3\mbWlvcGmkaYTpc44hd2ZiaIXtZY4hSTZ5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWzMlg2KG6P MYjTRW5ITVJ?
human SF126 cell M1LXZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn3GTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUW3MlA4KG6P MXnTRW5ITVJ?
human SW872 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUiuPUBvVQ>? NIrtVWdUSU6JRWK=
human NCI-H1581 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{G3cmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVgyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjdwNkSgcm0> NVrWR3IzW0GQR1XS
human SK-MEL-5 cell NIHPZYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEf3fXJKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwMkWgcm0> NXzRXo0{W0GQR1XS
human CP50-MEL-B cell NGTUcJZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVPr[FhQUW6qaXLpeIlwdiCxZjDoeY1idiCFUEWwMW1GVC2EIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NkmuOVkhdk1? M{nZRnNCVkeHUh?=
human YH-13 cell NYGyRXJkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3G2OWlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23NE42QSCwTR?= M2\6T3NCVkeHUh?=
human LXF-289 cell NInuW2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWDVe2pHUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PzJwOEWgcm0> MnjTV2FPT0WU
human MC-IXC cell M2n1eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVLHW2xjUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04PS5|MzDuUS=> M4jjNnNCVkeHUh?=
human NB14 cell NUHoUIE1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH;NUllKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Ok41PSCwTR?= MkHIV2FPT0WU
human HEC-1 cell NE\5OWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGhGSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OEGuN|chdk1? M2DFd3NCVkeHUh?=
human U-87-MG cell NFr2Oo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHUuQDdvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24Nk4zPCCwTR?= MknaV2FPT0WU
human HOS cell NVrk[GVLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX7mTVlWUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24OE44OSCwTR?= M2GyNHNCVkeHUh?=
human HUTU-80 cell NYTNO4tST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4nwbGlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg4NjBzIH7N NWfYW3liW0GQR1XS
human A375 cell Mk\XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUDQO3JpUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFgvQDNibl2= M1vaeHNCVkeHUh?=
human A204 cell NYjUXGNUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1K1fWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm3Mlg1KG6P NHTO[nRUSU6JRWK=
human GB-1 cell MmnPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF30PIhKdmirYnn0bY9vKG:oIHj1cYFvKEeELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25PE43QSCwTR?= M4\NR3NCVkeHUh?=
human MDA-MB-231 cell MnfhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkD5TY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMEiwO{DPxE1? NHfwZnNUSU6JRWK=
human SW982 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MorhTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVExPyEQvF2= NX75TXExW0GQR1XS
human SW756 cell NYrtUpBET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M330NGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5NU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjN4IN88US=> MYfTRW5ITVJ?
human MG-63 cell NXu0WJY6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF\mWJVKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTJ2ODFOwG0> NFXlTnZUSU6JRWK=
human Daoy cell NV\yVIRIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0NFc{KM7:TR?= M{HHdXNCVkeHUh?=
human MDA-MB-453 cell M4G4eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYHJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20OVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3MUi4JO69VQ>? NFzocWpUSU6JRWK=
human HT-144 cell MlXQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3KzdGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTJyMTFOwG0> NVnyUGNmW0GQR1XS
human LoVo cell MnvOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnnPTY5pcWKrdHnvckBw\iCqdX3hckBNd1[xIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOlA6OyEQvF2= M2excHNCVkeHUh?=
human NY cell NHrqS5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn;aTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUe3OlIh|ryP MUnTRW5ITVJ?
human SW1783 cell NGOxb|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzoTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5OEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyOzBzIN88US=> MWjTRW5ITVJ?
human A2780 cell NYL0[Gh4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXu1[ZViUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjF6NE[g{txO NYLrWlJHW0GQR1XS
human MDA-MB-361 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ{NkSg{txO NYCxUXlJW0GQR1XS
human RPMI-2650 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWrJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvMk[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN6M{Gg{txO M{fxe3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol

Kinase Assay:[1]
- Collapse

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
Cell Research:[2]
- Collapse
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C1=CC=CC=C1CC2=CC(=C(O)C(=C2O)O)C(=O)NC3=CC=C(C=C3)[S](=O)(=O)C4=C(C=CC=C4)C(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID